T1	Outcomes 1282 1316	attain blood trough concentrations
T2	Outcomes 2071 2088	reduction in SEGA
T3	Outcomes 2104 2133	39·0-58·3), and duration of
T4	Outcomes 2185 2198	not reached).
T5	Outcomes 2382 2395	at 144 weeks.
T6	Outcomes 2417 2436	patients) and mouth
T7	Outcomes 2509 2524	adverse events;
T8	Outcomes 2686 2706	grade 3 or 4 adverse
T9	Outcomes 2731 2744	of which were
T10	Outcomes 2756 2771	(nine [8%]) and
T11	Outcomes 2804 2850	patients had treatment-related serious adverse
T12	Outcomes 2877 2904	withdrew because of adverse
T13	Outcomes 3106 3121	manifestations.
T14	Outcomes 3122 3158	Reduction or stabilisation of tumour
